{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:11:06Z","timestamp":1767665466932},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0160436","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T17:50:55Z","timestamp":1470937855000},"page":"e0160436","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Ting-Tse","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Hsu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiunn-Lee","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juey-Jen","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"issue":"6865","key":"ref1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"P Zimmet","year":"2001","journal-title":"Nature"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"SM Haffner","year":"1998","journal-title":"N Engl J Med"},{"issue":"17","key":"ref3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"MJ Sarnak","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"ref4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"RR Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/diacare.23.10.1478","article-title":"Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators","volume":"23","author":"SR Levin","year":"2000","journal-title":"Diabetes Care"},{"issue":"9131","key":"ref6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199307293290502","article-title":"The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus","volume":"329","author":"P Reichard","year":"1993","journal-title":"N Engl J Med"},{"issue":"12A","key":"ref8","first-page":"4i","article-title":"Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"DC Goff Jr.","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"W Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"ref10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"A Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s002280050403","article-title":"Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function","volume":"53","author":"A Jonsson","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"T Inoue","year":"2003","journal-title":"Clin Nephrol"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ki.2015.96","article-title":"Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis","volume":"88","author":"TT Lin","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"DM Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"2 Suppl 2","key":"ref15","first-page":"S12","article-title":"KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice","volume":"12","author":"M Abe","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"4 Suppl 3","key":"ref17","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"9739","key":"ref18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"F Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"ref19","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"4","author":"SR Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: the safest hypoglycaemic agent in chronic kidney disease?","volume":"118","author":"HJ Nye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"ref21","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(02)00242-5","article-title":"Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure","volume":"59","author":"T Nagai","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"C Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/147323000203000405","article-title":"Pharmacokinetics of rosiglitazone in patients with end-stage renal disease","volume":"30","author":"K Thompson-Culkin","year":"2002","journal-title":"J Int Med Res"},{"key":"ref25","first-page":"S48","article-title":"Carbohydrate and insulin metabolism in renal failure","volume":"62","author":"A Alvestrand","year":"1997","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1978.03630270043017","article-title":"Decreased insulin requirement in acute renal failure in diabetic nephropathy","volume":"138","author":"LA Weinrauch","year":"1978","journal-title":"Arch Intern Med"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/ki.1992.414","article-title":"Glucose homeostasis and the kidney","volume":"42","author":"HJ Adrogue","year":"1992","journal-title":"Kidney Int"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease","volume":"17","author":"RW Snyder","year":"2004","journal-title":"Semin Dial"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.ijcard.2012.06.108","article-title":"Epidemiology and mortality among dialysis patients with acute coronary syndrome: Taiwan National Cohort Study","volume":"167","author":"MT Chou","year":"2013","journal-title":"Int J Cardiol"},{"issue":"14","key":"ref30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"BM Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"JB Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"ref32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"WB White","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2337\/dc09-2176","article-title":"Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis","volume":"33","author":"E Sobngwi","year":"2010","journal-title":"Diabetes Care"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jamainternmed.2014.5294","article-title":"Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study","volume":"174","author":"SA Berkowitz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dc08-9026","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association","volume":"32","author":"JS Skyler","year":"2009","journal-title":"Diabetes Care"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0160436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T01:07:28Z","timestamp":1540256848000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0160436"}},"subtitle":[],"editor":[{"given":"Karin","family":"Jandeleit-Dahm","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0160436","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]}}}